Pills are displayed with open pill bottles on top of a white counter top in the kitchen.Viking Therapeutics (VKTX) released ...
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
On Wednesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $65.85 which represents a slight increase of $0.47 or 0.72% from the prior close of $65.38. The stock opened ...
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price ...
Viking Therapeutics, Inc. (VKTX) closed at $65.85 in the latest trading session, marking a +0.72% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.47%. On the ...
That's more than enough to cover its operating cash burn, which over the trailing 12 months has totaled just under $72 million. Even if its rate of cash burn accelerates, Viking looks to have ...
Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.